Verhagen Metman L, Del Dotto P, Blanchet P J, van den Munckhof P, Chase T N
National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Amino Acids. 1998;14(1-3):75-82. doi: 10.1007/BF01345246.
In animal models of Parkinson's disease (PD), glutamate antagonists diminish levodopa (LD)-associated motor fluctuations and dyskinesias. We sought to investigate if these preclinical observations can be extended to the human disease, by evaluating the effects of three non-competitive NMDA antagonists (dextrorphan, dextromethorphan and amantadine) on the motor response to LD in patients with advanced PD. In four separate trials, adjuvant therapy with these drugs reduced LD-induced dyskinesias and motor fluctuations. These findings support the view that drugs acting to inhibit glutamatergic transmission at the NMDA receptor can ameliorate LD associated motor response complications.
在帕金森病（PD）动物模型中，谷氨酸拮抗剂可减少左旋多巴（LD）相关的运动波动和异动症。我们试图通过评估三种非竞争性N-甲基-D-天冬氨酸（NMDA）拮抗剂（右啡烷、右美沙芬和金刚烷胺）对晚期PD患者LD运动反应的影响，来研究这些临床前观察结果是否能推广到人类疾病。在四项独立试验中，这些药物的辅助治疗减少了LD诱发的异动症和运动波动。这些发现支持了这样一种观点，即作用于抑制NMDA受体处谷氨酸能传递的药物可改善LD相关的运动反应并发症。
